Literature DB >> 17030285

Vaginal microbicides.

Rebecca Flynn O'Brien1.   

Abstract

This article reviews the current status of microbicide development and challenges faced in developing safe and effective compounds. The ever growing HIV pandemic, lack of effective vaccines against HIV and other sexually transmitted infections, concern about the vulnerability of women, and difficulty in condom negotiation are factors that drive the development of topical microbicides as a prophylactic method for women. The ideal microbicide needs to be safe and highly effective and not increase viral resistance or cause disruption of host defenses. Advances in the understanding of HIV transmission and the role of other sexually transmitted infections have allowed progress in development of microbicide candidates as clinical trials of potential agents are awaited.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17030285     DOI: 10.1016/j.admecli.2006.06.004

Source DB:  PubMed          Journal:  Adolesc Med Clin        ISSN: 1041-3499


  2 in total

1.  Development of a comprehensive human immunodeficiency virus type 1 screening algorithm for discovery and preclinical testing of topical microbicides.

Authors:  Carol Lackman-Smith; Clay Osterling; Katherine Luckenbaugh; Marie Mankowski; Beth Snyder; Gareth Lewis; Jeremy Paull; Albert Profy; Roger G Ptak; Robert W Buckheit; Karen M Watson; James E Cummins; Brigitte E Sanders-Beer
Journal:  Antimicrob Agents Chemother       Date:  2008-03-03       Impact factor: 5.191

2.  Limitations of the dye-based method for determining vaginal applicator use in microbicide trials.

Authors:  Michele N Austin; Lorna K Rabe; Sharon L Hillier
Journal:  Sex Transm Dis       Date:  2009-06       Impact factor: 2.830

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.